PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment

Biomaterials

Volumn 35, Issue 30, 2014, Pages 8723-8734

  Ma, Hecheng ^a   He, Chaoliang ^b   Cheng, Yilong ^b   Li, Dongsong ^a   Gong, Yubao ^a   Liu, Jianguo ^a   Tian, Huayu ^b   Chen, Xuesi ^b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

Author keywords

Combination therapy; Injectable hydrogel; Localized delivery; Osteosarcoma; PLK1 silencing; Synergistic effect

Indexed keywords

CELL DEATH; COPOLYMERS; MAMMALS; TUMORS;

COMBINATION THERAPY; INJECTABLE HYDROGELS; LOCALIZED DELIVERY; OSTEOSARCOMA; PLK1 SILENCING; SYNERGISTIC EFFECT;

HYDROGELS;

DOXORUBICIN; MACROGOL; POLO LIKE KINASE 1; POLYETHYLENEIMINE; SHORT HAIRPIN RNA; CELL CYCLE PROTEIN; HYDROGEL; LACTIC ACID; LYSINE; ONCOPROTEIN; POLO-LIKE KINASE 1; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; SOLUTION AND SOLUBILITY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE REGULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EX VIVO STUDY; HEAT SENSITIVITY; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; SAOS 2 CELL LINE; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; CELL DEATH; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; METABOLISM; NICK END LABELING; NUDE MOUSE; PATHOLOGY; PHASE TRANSITION; SOLUTION AND SOLUBILITY; SYNTHESIS; TISSUE DISTRIBUTION; WISTAR RAT;

MUS; MUS MUSCULUS;

ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; CELL DEATH; CELL LINE; CELL SURVIVAL; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGELS; IN SITU NICK-END LABELING; LACTIC ACID; LYSINE; MALE; MICE, NUDE; OSTEOSARCOMA; PHASE TRANSITION; POLYETHYLENEIMINE; POLYGLYCOLIC ACID; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RATS, WISTAR; RNA, SMALL INTERFERING; SOLUTIONS; TISSUE DISTRIBUTION; TRANSFECTION;

EID: 84904758512     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.06.045     Document Type: Article

References (65)

1. Ward E., DeSantis C., Robbins A., Kohler B., Jemal A. Childhood and adolescent cancer statistics. CA Cancer J Clin 2014, 2014(64):83-103.
2. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010, 36:277-285.
3. Bielack S.S., Kempf-Bielack B., Delling G., Exner G.U., Flege S., Helmke K., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20:776-790.
4. Gatta G., Botta L., Rossi S., Aareleid T., Bielska Lasota M., Clavel J., et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-a population-based study. Lancet Oncol 2014, 15:35-47.
5. Stiller C.A., Trama A., Serraino D., Rossi S., Navarro C., Chirlaque M.D., et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 2013, 49:684-695.
6. Berrino F., De Angelis R., Sant M., Rosso S., Lasota M.B., Coebergh J.W., et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007, 8:773-783.
7. Guo D.D., Hong S.H., Jiang H.L., Kim J.H., Minai Tehrani A., Kim J.E., et al. Synergistic effects of Akt1 shRNA and paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel on breast cancer. Biomaterials 2012, 33:2272-2281.
8. Ta H.T., Dass C.R., Larson I., Choong P.F., Dunstan D.E. A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy. Biomaterials 2009, 30:4815-4823.
9. Gill J., Ahluwalia M.K., Geller D., Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther 2013, 137:89-99.
10. Broadhead M.L., Clark J.C., Choong P.F., Dass C.R. Making gene therapy for osteosarcoma a reality. Expert Rev Anticancer Ther 2010, 10:477-480.
11. Anninga J.K., Gelderblom H., Fiocco M., Kroep J.R., Taminiau A.H.M., Hogendoorn P.C.W., et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?. Eur J Cancer 2011, 47:2431-2445.
12. Luetke A., Meyers P.A., Lewis I., Juergens H. Osteosarcoma treatment-where do we stand? a state of the art review. Cancer Treat Rev 2014, 40:523-532.
13. McTiernan A., Jinks R.C., Sydes M.R., Uscinska B., Hook J.M., van Glabbeke M., et al. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European osteosarcoma intergroup. Eur J Cancer 2012, 48:703-712.
14. Janeway K.A., Grier H.E. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 2010, 11:670-678.
15. Cortes E.P., Holland J.F., Wang J.J., Sinks L.F., Blom J., Senn H., et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 1974, 291:998-1000.
16. Carter S.K., Blum R.H. New chemotherapeutic agents-bleomycin and adriamycin. CA Cancer J Clin 1974, 24:322-331.
17. Pang B., Qiao X., Janssen L., Velds A., Groothuis T., Kerkhoven R., et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun 2013, 4:1908.
18. Swift L.P., Rephaeli A., Nudelman A., Phillips D.R., Cutts S.M. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006, 66:4863-4871.
19. Hayek E.R., Speakman E., Rehmus E. Acute doxorubicin cardiotoxicity. N Engl J Med 2005, 352:2456-2457.
20. Barr F.A., Silljé H.H., Nigg E.A. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004, 5:429-441.
21. Kasahara K., Goto H., Izawa I., Kiyono T., Watanabe N., Elowe S., et al. PI 3-kinase-dependent phosphorylation of Plk1-Ser99 promotes association with 14-3-3γ and is required for metaphase-anaphase transition. Nat Commun 2013, 4:1882.
22. Petronczki M., Lénárt P., Peters J.-M. Polo on the rise - from mitotic entry to cytokinesis with Plk1. Dev Cell 2008, 14:646-659.
23. Martin B.T., Strebhardt K. Polo-like kinase. Cell Cycle 2006, 5:2881-2885.
24. Eckerdt F., Yuan J., Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005, 24:267-276.
25. Simizu S., Osada H. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat Cell Biol 2000, 2:852-854.
26. Knecht R., Elez R., Oechler M., Solbach C., von Ilberg C., Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59:2794-2797.
27. Duan Z., Ji D., Weinstein E.J., Liu X., Susa M., Choy E., et al. Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. Cancer Lett 2010, 293:220-229.
28. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006, 6:321-330.
29. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
30. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
31. Mittal V. Improving the efficiency of RNA interference in mammals. Nat Rev Genet 2004, 5:355-365.
32. He C., Zhuang X., Tang Z., Tian H., Chen X. Stimuli-sensitive synthetic polypeptide-based materials for drug and gene delivery. Adv Healthc Mater 2012, 1:48-78.
33. Tian H., Lin L., Jiao Z., Guo Z., Chen J., Gao S., et al. Polylysine-modified polyethylenimine inducing tumor apoptosis as an efficient gene carrier. J Control Release 2013, 172:410-418.
34. He C., Kim S.W., Lee D.S. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J Control Release 2008, 127:189-207.
35. Yu L., Ding J. Injectable hydrogels as unique biomedical materials. Chem Soc Rev 2008, 37:1473-1481.
36. Zentner G.M., Rathi R., Shih C., McRea J.C., Seo M.-H., Oh H., et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 2001, 72:203-215.
37. Kim Y.J., Choi S., Koh J.J., Lee M., Ko K.S., Kim S.W. Controlled release of insulin from injectable biodegradable triblock copolymer. Pharm Res 2001, 18:548-550.
38. Jeong J.H., Kim S.W., Park T.G. Biodegradable triblock copolymer of PLGA-PEG-PLGA enhances gene transfection efficiency. Pharm Res 2004, 21:50-54.
39. Moffatt S., Cristiano R.J. Uptake characteristics of NGR-coupled stealth PEI/pDNA nanoparticles loaded with PLGA-PEG-PLGA triblock copolymer for targeted delivery to human monocyte-derived dendritic cells. Int J Pharm 2006, 321:143-154.
40. Lee P.Y., Li Z., Huang L. Thermosensitive hydrogel as a Tgf-β1 gene delivery vehicle enhances diabetic wound healing. Pharm Res 2003, 20:1995-2000.
41. Li Z., Ning W., Wang J., Choi A., Lee P.Y., Tyagi P., et al. Controlled gene delivery system based on thermosensitive biodegradable hydrogel. Pharm Res 2003, 20:884-888.
42. Sohn L.L., Saleh O.A., Facer G.R., Beavis A.J., Allan R.S., Notterman D.A. Capacitance cytometry: measuring biological cells one by one. Proc Natl Acad Sci U S A 2000, 97:10687-10690.
43. Pidgeon G.P., Kandouz M., Meram A., Honn K.V. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res 2002, 62:2721-2727.
44. Carlsson G., Gullberg B., Hafström L. Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 1983, 105:20-23.
45. Yu L., Zhang Z., Zhang H., Ding J. Mixing a sol and a precipitate of block copolymers with different block ratios leads to an injectable hydrogel. Biomacromolecules 2009, 10:1547-1553.
46. Lee D.S., Shim M.S., Kim S.W., Lee H., Park I., Chang T. Novel thermoreversible gelation of biodegradable PLGA-block-PEO-block-PLGA triblock copolymers in aqueous solution. Macromol Rapid Commun 2001, 22:587-592.
47. Qiao M., Chen D., Ma X., Liu Y. Injectable biodegradable temperature-responsive PLGA-PEG-PLGA copolymers: synthesis and effect of copolymer composition on the drug release from the copolymer-based hydrogels. Int J Pharm 2005, 294:103-112.
48. Kang Y.M., Lee S.H., Lee J.Y., Son J.S., Kim B.S., Lee B., et al. A biodegradable, injectable, gel system based on MPEG-b-(PCL-ran-PLLA) diblock copolymers with an adjustable therapeutic window. Biomaterials 2010, 31:2453-2460.
49. Yu L., Zhang Z., Zhang H., Ding J. Biodegradability and biocompatibility of thermoreversible hydrogels formed from mixing a sol and a precipitate of block copolymers in water. Biomacromolecules 2010, 11:2169-2178.
50. Cheng Y., He C., Ding J., Xiao C., Zhuang X., Chen X. Thermosensitive hydrogels based on polypeptides for localized and sustained delivery of anticancer drugs. Biomaterials 2013, 34:10338-10347.
51. Bos G.W., Hennink W.E., Brouwer L.A., den Otter W., Veldhuis T.F.J., van Nostrum C.F., et al. Tissue reactions of in situ formed dextran hydrogels crosslinked by stereocomplex formation after subcutaneous implantation in rats. Biomaterials 2005, 26:3901-3909.
52. Wu L., Ding J. In vitro degradation of three-dimensional porous poly(d,l-lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials 2004, 25:5821-5830.
53. Liu X., Erikson R.L. Polo-like kinase 1 in the life and death of cancer cells. Cell Cycle 2003, 2:424-425.
54. Vermes I., Haanen C., Steffens Nakken H., Reutellingsperger C. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 1995, 184:39-51.
55. García-Sáez A. The secrets of the Bcl-2 family. Cell Death Differ 2012, 19:1733-1740.
56. Devarajan E., Sahin A.A., Chen J.S., Krishnamurthy R.R., Aggarwal N., Brun A.-M., et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 2002, 21:8843-8851.
57. Fujita E., Egashira J., Urase K., Kuida K., Momoi T. Caspase-9 processing by caspase-3 via a feedback amplification loop in vivo. Cell Death Differ 2001, 8:335-344.
58. Larsen B.D., Rampalli S., Burns L.E., Brunette S., Dilworth F.J., Megeney L.A. Caspase 3/caspase-activated DNase promote cell differentiation by inducing DNA strand breaks. Proc Natl Acad Sci U S A 2010, 107:4230-4235.
59. Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999, 68:383-424.
60. Hockenbery D., Nuñez G., Milliman C., Schreiber R.D., Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348:334-336.
61. Srinivasula S.M., Hegde R., Saleh A., Datta P., Shiozaki E., Chai J., et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001, 410:112-116.
62. Nihal M., Stutz N., Schmit T., Ahmad N., Wood G.S. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis. Cell Cycle 2011, 10:1303-1311.
63. Hu K., Lee C., Qiu D., Fotovati A., Davies A., Abu Ali S., et al. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 2009, 8:3024-3035.
64. Grinshtein N., Datti A., Fujitani M., Uehling D., Prakesch M., Isaac M., et al. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 2011, 71:1385-1395.
65. Spänkuch B., Matthess Y., Knecht R., Zimmer B., Kaufmann M., Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004, 96:862-872.